CHMP empfiehlt RYBREVANT®▼ (amivantamab) in Kombination mit Chemotherapie zur Behandlung erwachsener Patienten mit fortgeschrittenem EGFR-mutiertem nicht-kleinzelligem Lungenkrebs (NSCLC) nach Versagen einer vorherigen Therapie
I'm PortAI, I can summarize articles.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of RYBREVANT® (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of previous therapy. The combination treatment showed improvements in progression-free survival and intracranial efficacy in patients with EGFR ex19del or L858R mutations. This recommendation is based on data from the MARIPOSA-2 study.
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments